Salarius Pharmaceuticals, Inc.
SLRXOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.8M | $5.2M |
| Operating income | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M |
| Net income | −$12.5M | −$5.6M | −$12.5M | −$31.6M | −$12.8M | −$7.4M |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M | $24.9M |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M | $2.8M |
| Equity | $5.9M | $1.5M | $5.3M | $10.4M | $38.7M | $22.2M |
| EPS (diluted) | $-129.10 | $-5.79 | $-30.74 | $-14.88 | $-7.72 | $-0.50 |
| Shares out. | 1.7M | 4.3M | 2.5M | 46.7M | 44.7M | 13.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −212.6%
- Return on assets
- −113.2%
- Return on capital (ROCE)
- −214.2%
- Liabilities / assets
- 46.7%
- Debt / equity
- 0.88×
- Book value / share
- $3.37
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -30.86distress
- Accruals / assets
- −69.6%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cvi Investments, Inc.Passive (13G)Feb 17, 2026
- Intracoastal Capital, LlcPassive (13G)Nov 14, 2025
- C/M Capital Partners, LpPassive (13G)Oct 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Hanish Arnold CDirector | Dec 30, 2025 | Sell | 15 | $0.64 |
| Hanish Arnold CDirector | Nov 20, 2025 | Buy | 5,000 | $0.75 |
| Rosenblum Mark JOfficer — Exec VP Finance, CFO | Nov 20, 2025 | Buy | 20,000 | $0.80 |
| Rosenblum Mark JOfficer — Exec VP Finance, CFO | Feb 13, 2023 | Grant | 6,432 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Dec 31, 2025 | 223,283 | 1.0 | +20.9% |
| Dec 15, 2025 | 184,642 | 1.0 | +0.2% |
| Nov 28, 2025 | 184,255 | 1.0 | -60.6% |
| Nov 14, 2025 | 467,881 | 1.0 | +29.9% |
| Oct 31, 2025 | 360,165 | 3.6 | +2.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Item 5.08 · Other material eventMay 19, 2026
- Other material eventApr 2, 2026
- Modified shareholder rights · Amended charter or bylaws · Other material eventMar 5, 2026
- Shareholder voteFeb 25, 2026
- Amended charter or bylaws · Other material eventJan 8, 2026
- Delisting / listing-standard noticeJan 2, 2026
- Shareholder voteJan 2, 2026
- Shareholder vote · Regulation FD disclosureDec 19, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.